Bavarian Nordic News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.03.18	Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine (GlobeNewswire)
26.02.18	Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers (GlobeNewswire)
06.02.18	Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine (GlobeNewswire)
31.01.18	Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen (GlobeNewswire)
19.01.18	Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis (GlobeNewswire)
21.11.17	Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine (GlobeNewswire)
09.11.17	Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine (GlobeNewswire)
08.11.17	Bavarian Nordic Announces Interim Results for the First Nine Months of 2017 (GlobeNewswire)
27.09.17	Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government (GlobeNewswire)
21.09.17	Bavarian Nordic Provides Update on its Universal RSV Vaccine (GlobeNewswire)
14.09.17	Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer (GlobeNewswire)
14.09.17	Bavarian Nordic to Host Capital Markets Day in New York City (GlobeNewswire)
11.09.17	Principal Investigator Dr. James Gulley to Provide Presentation Entitled "Therapeutic Vaccines in Prostate Cancer" at the ESMO 2017 Congress (GlobeNewswire)
25.08.17	Bavarian Nordic Announces First Half 2017 Results (GlobeNewswire)
22.08.17	Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation - Inc. (GlobeNewswire)
21.08.17	Bavarian Nordic Announces Closing of Transaction with Janssen Pharmaceuticals, Inc. and Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc. (GlobeNewswire)
18.08.17	Bavarian Nordic to Host First Half 2017 Results Conference Call (GlobeNewswire)
09.08.17	Bavarian Nordic Announces Subscription Price and Number of Shares to be Issued to Johnson & Johnson Innovation - JJDC, Inc. (GlobeNewswire)
27.07.17	Bavarian Nordic Announces Additional Details Regarding the Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc. (GlobeNewswire)
27.07.17	Bavarian Nordic Announces Agreement with Janssen for the Development of Vaccine Regimens against HIV-1 and Hepatitis B (GlobeNewswire)
23.11.16	Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE® Smallpox Vaccine (GlobeNewswire)
23.11.16	Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise (GlobeNewswire)
10.11.16	Bavarian Nordic to Present at Jefferies 2016 London Healthcare Conference (GlobeNewswire)
09.11.16	Bavarian Nordic Announces Interim Results for the First Nine Months of 2016 (GlobeNewswire)
01.11.16	Bavarian Nordic to Host Third Quarter 2016 Results Conference Call (GlobeNewswire)
18.10.16	Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine (GlobeNewswire)
10.10.16	Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC and Ipilimumab in Patients with Localized Prostate Cancer (GlobeNewswire)
29.09.16	Bavarian Nordic Announces Presentation of Phase 1 Data for its RSV Vaccine at International RSV Symposium (GlobeNewswire)
28.09.16	Bavarian Nordic Appoints Christopher Heery, M.D., as Chief Medical Officer (GlobeNewswire)
13.09.16	Bavarian Nordic Issues Financial Calendar for 2017 (GlobeNewswire)
12.09.16	Bavarian Nordic Announces that Janssen has completed a Submission for Emergency Use Assessment and Listing for its Ebola Vaccine Regimen to the World Health Organization (GlobeNewswire)
17.08.16	Bavarian Nordic Announces First Half 2016 Results (GlobeNewswire)
15.08.16	Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study (GlobeNewswire)
27.07.16	Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine (GlobeNewswire)
15.06.16	Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government (GlobeNewswire)
02.06.16	Bavarian Nordic to Present at Jefferies 2016 Healthcare Conference in New York (GlobeNewswire)
26.05.16	Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations (GlobeNewswire)
23.05.16	Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations (GlobeNewswire)
19.05.16	Bavarian Nordic Announces USD 100 Million Supply Contract for IMVAMUNE Smallpox Vaccine with the U.S. Government (GlobeNewswire)
13.05.16	Bavarian Nordic Announces Interim Results for the First Three Months of 2016 (GlobeNewswire)
09.05.16	Bavarian Nordic to Host First Quarter 2016 Results Conference Call (GlobeNewswire)
19.04.16	Bavarian Nordic Applauds Announcement of Positive Data for Ebola Vaccine Regimen Published in JAMA (GlobeNewswire)
21.03.16	Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise (GlobeNewswire)
07.03.16	Bavarian Nordic Awards Restricted Stock Units to Executive Management (GlobeNewswire)
07.03.16	Bavarian Nordic Announces Annual Report 2015 (GlobeNewswire)
22.02.16	Bavarian Nordic Announces New Date for Publication of its 2015 Annual Report (GlobeNewswire)
04.02.16	Bavarian Nordic Enters Research Collaboration to Develop MRSA Vaccine (GlobeNewswire)
05.01.16	Bavarian Nordic Announces 3:1 Effective Split of American Depositary Shares (GlobeNewswire)
04.01.16	Bavarian Nordic Files Registration Statement for Proposed Initial Public Offering of ADSs in the United States (GlobeNewswire)
18.12.15	Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV Vaccine (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

22.08.24		Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen
22.08.24		Ausblick: Bavarian Nordic legt Quartalsergebnis vor
20.08.24		Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an
23.08.22		Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

22.08.24

Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen

22.08.24

Ausblick: Bavarian Nordic legt Quartalsergebnis vor

20.08.24

Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an

23.08.22

Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bavarian Nordic A/S

Aktien Top/Flop

Bavarian Nordic Peer Group Nachrichten

Meistgelesene Nachrichten